Aflatoxins and growth impairment: A review Original paper
Researched by:
-
Dr. Umar
ID
Dr. Umar
Read MoreClinical Pharmacist and Clinical Pharmacy Master’s candidate focused on antibiotic stewardship, AI-driven pharmacy practice, and research that strengthens safe and effective medication use. Experience spans digital health research with Bloomsbury Health (London), pharmacovigilance in patient support programs, and behavioral approaches to mental health care. Published work includes studies on antibiotic use and awareness, AI applications in medicine, postpartum depression management, and patient safety reporting. Developer of an AI-based clinical decision support system designed to enhance antimicrobial stewardship and optimize therapeutic outcomes.
-
Dr. Umar
Read More
Researched by:
-
Dr. Umar
ID
Dr. Umar
Read More
Microbiome Signatures identifies and validates condition-specific microbiome shifts and interventions to accelerate clinical translation. Our multidisciplinary team supports clinicians, researchers, and innovators in turning microbiome science into actionable medicine.
Dr. Umar
What was reviewed?
This review examines the evidence that aflatoxin growth impairment is a clinically meaningful relationship, beyond aflatoxin’s well-established hepatocarcinogenicity. The authors synthesize animal toxicology, human epidemiology, and biomarker research to evaluate whether dietary aflatoxin exposure—primarily from maize and groundnuts contaminated by Aspergillus flavus and A. parasiticus—contributes to childhood stunting, underweight, and wasting in regions where both exposure and malnutrition are common. The paper emphasizes how validated biomarkers (notably serum aflatoxin–albumin adducts and aflatoxin M1 in biological fluids) have strengthened recent human studies and enabled dose–response analyses, a key step toward causal inference.
Who was reviewed?
The review covers multiple populations across Africa, Asia, and the Middle East, with particular attention to infants and young children during weaning—a period when exposure rises sharply as diets shift toward maize- and groundnut-based complementary foods. It also includes pregnant and lactating women because fetal exposure (cord blood biomarkers) and postnatal transfer (breast milk AFM1) represent early-life exposure pathways. The authors highlight data from West Africa (Benin, Togo, Gambia, Ghana), East Africa (Kenya), and several Asian/Middle Eastern settings (Iran, UAE, Thailand), where biomarker positivity is frequent and growth faltering is prevalent.
Most important findings
Across animal studies, aflatoxin exposure consistently reduced weight gain, feed intake, and feed conversion efficiency, and in utero exposure impaired offspring growth—supporting biological plausibility for human effects. In humans, the most compelling evidence comes from West African biomarker studies showing dose–response relationships between aflatoxin–albumin adducts (AF-alb) and poorer growth indices (HAZ, WAZ, and sometimes WHZ). Children who were fully weaned had roughly higher exposure than partially breastfed children, aligning exposure timing with the window of rapid linear growth faltering. Longitudinal data in Benin showed reduced height velocity with higher AF-alb, strengthening temporality. Maternal exposure also mattered: studies linked higher maternal/cord biomarkers with lower birth weight and reduced infant growth in the first year, suggesting that fetal exposure may “program” early growth trajectories. Mechanistically, the review proposes pathways relevant to microbiome research: aflatoxin-associated immunomodulation may increase infection susceptibility, while impaired intestinal integrity could heighten vulnerability to enteric microbes—conceptually intersecting with environmental enteric dysfunction and dysbiosis-driven inflammation, even though the reviewed studies did not directly measure the gut microbiome.
| Microbiome-relevant signature | Clinical/growth association highlighted |
|---|---|
| Reduced mucosal immune resilience (lower sIgA context) | Higher aflatoxin biomarkers associated with impaired growth indices and immune effects |
| Increased enteric infection susceptibility | Proposed mediator linking aflatoxin exposure to growth faltering |
| Intestinal barrier dysfunction / increased permeability risk | Proposed route for greater exposure to luminal microbes and inflammatory growth suppression |
| Weaning-diet transition to maize/groundnuts (high exposure window) | Exposure spikes after weaning; aligns with peak stunting accrual in early childhood |
Key implications
For clinicians, this review reframes aflatoxin not only as a carcinogen but also as a potential upstream contributor to pediatric undernutrition in high-exposure regions, acting alongside infections, poverty, and suboptimal diets. It supports integrating aflatoxin risk assessment into maternal–child health, especially around weaning, and strengthens the rationale for interventions that reduce toxin load in staple foods (biocontrol, improved storage, safer weaning foods). For microbiome-informed practice and databases, the key translational signal is that aflatoxin may drive growth impairment through immune and gut-integrity pathways that plausibly interact with dysbiosis and enteric inflammation—making aflatoxin exposure an important exposure variable when interpreting microbiome–growth associations in low-resource settings.
Citation
Khlangwiset P, Shephard GS, Wu F. Aflatoxins and growth impairment: A review.Critical Reviews in Toxicology. 2011;41(9):740-755. doi:10.3109/10408444.2011.575766